US-based biotech Cerevance is continuing an ongoing pivotal study of its Parkinson’s disease candidate despite it showing no benefit compared to placebo in a Phase II study. The biotech ...

Cerevance’s attempt to unlock the first-line Parkinson's disease market has hit a snag, with solengepras performing no better than placebo in phase 2 when given to people with early, untreated ...

Additional Cerevance Presentations at AAN 2025The company presented a poster demonstrating the potential of its proprietary NETSseq platform to identify and/or validate cell-specific gene targets ...

Cerevance, a clinical-stage biopharmaceutical company advancing multiple cell type-specific therapies for the treatment of neurodegenerative, psychiatric, and central nervous system-controlled ...

On 2 April, at the AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s Disease, Cerevance announced that solengepras failed to meet its primary endpoint—change from baseline ...

Brian Gormley covers venture capital and healthcare for The Wall Street Journal.

Solengepras, the most advanced investigational treatment in Cerevance's pipeline, is an oral, non-dopaminergic therapy in Phase 3 development for Parkinson's disease. A brain-penetrant, specific ...

KCNK13 was identified by Cerevance's proprietary NETSseq platform. About Solengepras (formerly CVN424) Solengepras is designed to provide a potentially novel approach to the treatment of Parkinson's ...